Bedaquiline resistance and genetic resistance associated variants: South African National Bedaquiline Surveillance program 2014–2019
نویسندگان
چکیده
منابع مشابه
A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment.
tuberculosis prevention, care and control after 2015. Geneva, WHO, 2014. 13 World Health Organization. Definitions and reporting framework for tuberculosis – 2013 revision. Geneva, WHO, 2013. 14 Van Deun A, Maug AK, Bola V, et al. Rifampicin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 2013; 51: 2633–2640. 15 Salje H, Andrews JR, Deo S, et al. The impo...
متن کاملDefining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study
BACKGROUND Bedaquiline (BDQ) is a novel agent approved for use in combination treatment of multi-drug resistant tuberculosis (MDR-TB). We sought to determine BDQ epidemiological cut-off values (ECVs), define and assess interpretive criteria against putative resistance associated variants (RAVs), microbiological outcomes and cross resistance with clofazimine (CFZ). METHODS A retrospective coho...
متن کاملAcquired Resistance of Mycobacterium tuberculosis to Bedaquiline
Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment of multi-drug resistant tuberculosis in decades. In vitro resistance to BDQ was previously shown to be due to target-based mutations. Here we report that non-target based resistance to BDQ, and cross-resistance to clofazimine (CFZ), is due to mutations in Rv0678, a transcriptional repressor of the genes...
متن کاملAcquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.
Treatment of multidrug-resistant Mycobacterium tuberculosis is a challenge. This letter describes the emergence of resistance to new therapies, bedaquiline and delamanid.
متن کاملUnexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline
Objectives Resistance-associated variants (RAVs) in Rv0678 , a regulator of the MmpS5-MmpL5 efflux pump, have been shown to lead to increased MICs of bedaquiline (2- to 8- fold) and clofazimine (2- to 4-fold). The prevalence of these Rv0678 RAVs in clinical isolates and their impact on treatment outcomes are important factors to take into account in bedaquiline treatment guidelines. Methods B...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Infectious Diseases
سال: 2020
ISSN: 1201-9712
DOI: 10.1016/j.ijid.2020.09.075